Summary We have previously shown that a short course of recombinant (3 million units day for 5 days) for patients with primary gynaecologic malignancies was able to increase the circulating levels of a newly discovered tumour associated antigen, termed 90K. In this study, we have investigated the effects of the same modality of administration of rIFN-alpha-2b in 62 patients with breast and colorectal cancer whose primary tumour was surgically removed I month before and who were without evidence of disease (NED) at the time of the study. A significant increase of 90K serum concentration was already observed 24 h after the first r-IFN-alpha-2b injection and persisted throughout the investigational period. The increase was more pronounced in patients with a basal 90K-negative than a 90K-positive assay. Of 54 patients who started the test with a 90K negative assay, 17 (31%) shifted to a positive assay after rIFN-alpha-2b. Twenty-eight of 62 (45%) patients exhibited a 90K value above the mean increment of the whole population. The serum levels of CEA, CA-15-3, CA 19-9, and alpha-fetoprotein measured in the same serum samples were not modified. After 2 years of follow-up, ten patients relapsed. Six of them showed a 90K increase above the mean increment of the whole population. As with ovarian cancer, the increase of 90K following r-IFN-alpha-2b administration might be of importance for the early detection of disease recurrence in clinically NED breast and colon cancer patients.
Summary We have previously shown that a short course of recombinant (3 million units day for 5 days) for patients with primary gynaecologic malignancies was able to increase the circulating levels of a newly discovered tumour associated antigen, termed 90K. In this study, we have investigated the effects of the same modality of administration of rIFN-alpha-2b in 62 patients with breast and colorectal cancer whose primary tumour was surgically removed I month before and who were without evidence of disease (NED) at the time of the study. A significant increase of 90K serum concentration was already observed 24 h after the first r-IFN-alpha-2b injection and persisted throughout the investigational period. The increase was more pronounced in patients with a basal 90K-negative than a 90K-positive assay. Of 54 patients who started the test with a 90K negative assay, 17 (31%) shifted to a positive assay after rIFN-alpha-2b. Twenty-eight of 62 (45%) patients exhibited a 90K value above the mean increment of the whole population. The serum levels of CEA, , and alpha-fetoprotein measured in the same serum samples were not modified. After 2 years of follow-up, ten patients relapsed. Six of them showed a 90K increase above the mean increment of the whole population. As with ovarian cancer, the increase of 90K following r-IFN-alpha-2b administration might be of importance for the early detection of disease recurrence in clinically NED breast and colon cancer patients. (Attallah et al., 1979; Liao et al., 1982; Greiner et al., 1984; Giacomini et al., 1985; Greiner et al., 1986a; Guadagni et al., 1987; Boyer et al., 1989; Marth et al., 1989; Guadagni et al., 1990) and in vivo in nude mice bearing transplanted human tumours (Greiner et al., 1986b; Rowlinson et al., 1986) . Moreover, we first reported (Iacobelli et al., 1988a) that the administration of recombinant interferon alpha-2b (rIFN-alpha-2b) in patients with breast cancer was able to augment the circulating levels of a 90,000 daltons TAA, termed 90K. This antigen which is identified by monoclonal antibody SP-2 (lacobelli et al., 1986) , is secreted into the tissue culture fluid of CG-5 human breast cancer cells and is found at increased concentrations in the serum of patients with various malignancies (Iacobelli et al., 1988b (Suter et al., 1988; Guesdon et al., 1979) . Coated beads were treated with an overcoating solution of bovine serum albumin (2 mg ml-') for 1 h at room temperature, washed with water and stored at room temperature until used. Beads treated in this fashion were stable for at least 6 months. With each dard were incubated with one SP-2-coated bead for 1 h at 37°C. After washing with distilled water, the beads were incubated with 100 pl of (Iacobelli et al., 1988b) . Moreover, the levels of 90K remained stable during daily measurement over a period of 10 consecutive days (unpublished results).
Serum CEA, CA 15-3, CA 19-9 and alpha-fetoprotein were measured by commercially available immunoassays kits (Sorin Biomedica, Saluggia, Italy). The coefficients or intraassay variation for CEA, CA 15-3, CA 19-9 and alphafetoprotein were 7.5%, 6%, 5%, and 8%, respectively and those for inter-assay variation 7.1%, 6.5%, 7.5%, and 5.9%, respectively. Cut-off limits for normal ranges were as follows: CEA, Sngml-'; CA 15-3, 30Uml-'; CA 19-9, 37Uml-', alpha-fetoprotein, 15 ng ml- '. Statistical analysis A Student's t-test for paired data was used to evaluate the modifications of TAAs during the 5 days of the test.
Results
Eight out of 62 (13%) patients had positive (>11 U ml-') 90K basal serum levels (7/49 breast carcinomas, 1/13 colorectal carcinomas). This rate of 90K positivity in NED cancer patients agrees with previous data (Iacobelli et al., 1988b) .
The administration of rIFN-alpha-2b significantly (P < 0.001) increased 90K serum levels over the mean of pretreatment values (Table I and Figure 1 ). The stimulatory effect was already evident 24 h after the first rIFN-alpha-2b administration and progressively increased throughout the period of observation. Patients with breast and colorectal cancer had similar pattern of response to rIFN-alpha-2b with maximal 90K increase of 39% and 56%, respectively.
As Figure 2 shows, the increase of 90K was more pronounced for patients who started the test with a negative (<11 U ml-') assay than for those with a positive assay (51% vs 27%). Moreover 17 of the 54 (31%) 90K-negative patients became 90K-positive after rIFN-alpha-2b with a similar proportion among breast cancers (13/49, 26%) and colorectal cancers (4/13, 31%). Considering that the mean increment of 90K in the whole population is 40%, then 28/62 (45%) patients exhibited an antigen increment above this value.
Neither CEA, nor CA 19-9, CA-15-3 or alpha-fetoprotein showed significant modifications during the 5 days of the test (Figure 3) . No remarkable side effects due to rIFN-alpha-2b administration were observed. Toxicity consisted of mild fever, fatigue and weakness in some cases.
After 2 years of follow-up, three patients with colorectal and seven with breast cancer relapsed. Among them, six patients (two colorectal and four breast cancer) showed a 90K increase following rIFN-alpha-2b administration higher than 40%, i.e. the mean 90K increment in the whole population; one breast cancer patient shifted from a negative to a positive value and two other breast cancer patients had very elevated pretreatment 90K (101 U ml1' and 26.7 U ml-') though their 90K values did not vary during the test. In the remaining relapsing patient with colorectal cancer 90K did not show any variation. 
Discussion
In a previous study (Scambia et al., 1990) , it was demonstrated that the preoperative administration of rIFN-alpha2b to patients with breast and gynaecologic cancer increased the circulating levels of 90K. The work reported here shows that the dynamic stimulation with rIFN-alpha-2b is also effective in patients with colorectal and breast cancer who are clinically NED after surgical removal of the primary tumour.
The significance of 90K rise in NED breast and colorectal cancer patients induced by rINF-alpha-2b
has not yet been established. Cure rate in these patients is 50-60% (Berger et al., 1988) ; some of these patients have micrometastatic disease already at the time of the primary surgery (Berger et al., 1988; Fisher & Turnbull, 1955) . Although in the absence of an adequate follow-up it is not possible to establish when the dynamic test has to be considered as 'true positive', i.e., leading to augmented antigen expression in those patients who will develop disease recurrence shortly after, two possibilities can be envisaged: either a shift from a negative (below the cut-off value) to a positive assay or a given increase of the antigen level irrespective of the basal value. In our series of patients, approximately one of three of them shifted from a negative to a positive 90K assay after rINFalpha-2b, whereas an augmentation of the antigen level above the mean increment of the whole population (40%) was seen in approximately one of two cases. Although the number of relapsing patients is too small to allow any statistical evaluation, it is meaningful that six out of ten of them exhibited an increase of 90K levels over 40%, whereas none but one shifted from a negative to a positive assay. The stimulatory effect of rIFN-alpha-2b on 90K in our patient population was more pronounced in antigen-negative than in antigen-positive patients. As suggested for other TAAs (Liao et al., 1982; Greiner et al., 1984) , this may reflect differences in sensitivity to rIFN-alpha-2b of genes and/or cellular elements involved in 90K production which could preferentially be stimulated when the constitutive 90K level is low. This same situation could explain why we failed to observe any increase of 90K after rIFN-alpha-2b in two relapsing patients with very high 90K pretreatment serum levels. If confirmed on a larger series, this could imply that the dynamic test should be performed only on patients exhibiting a negative 90K basal value.
Basal 90K levels were not modified by rIFN-alpha-2b in non-cancer patients including 12 women with genital condylomatosis (lacobelli et al., 1988a; Scambia et al., 1990) and in eight patients with chronic viral-B hepatitis (unpublished data (lacobelli et al., 1988a) . Therefore, assuming that increased 90K after rIFN-alpha-2b in our patients originates from enhanced production by occult cancer cells, the sensitivity of the assay is augmented of approximately three times. Finally, it is possible that the response to rIFNalpha-2b may be influenced by other factors such as the degree of differentiation of individual cancer, or intrinsic biological characteristics of the tumour as well as degradation rate of the 90K antigen.
The effect of rIFN-alpha-2b on 90K seems to have some specificity since neither CEA, nor CA 15-3, CA 19-9 or alpha-fetoprotein varied significantly during the 5 days of the test. A recent report (O'Connell et al., 1989) has shown that the administration of rIFN-gamma to patients with advanced metastatic colorectal carcinoma can enhance the circulating levels of CA 19-9 and to a lesser extent of CA 15-3. Similar to our findings, the increase was seen within 24 h after drug administration but it was independent of basal antigen level. Further studies using different types of interferon as well as optimal doses and timing of administration are required.
In conclusion, this serum test with rIFN-alpha-2b may be indicative of disease recurrence in clinically NED cancer patients. Its value in this setting is the focus of a large prospective clinical trial now under way at the University of Chieti Medical School.
